PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.
Year: 2011
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: R. W. Naumann, R. L. Coleman, R. A. Burger, T. J. Herzog, R. Morris, E. A. Sausville, E. Kutarska, S. A. Ghamande, N. Y. Gabrail, S. De Pasquale, E. Nowara, L. Gilbert, J. R. Caton, R. H. Gersh, M. G. Teneriello, W. A. Harb, P. Konstantinopoulos, J. T. Symanowski, C. Lovejoy, R. A. Messmann
Institutions: Fox Chase Cancer Center, The University of Texas MD Anderson Cancer Center, Wayne State University, Carolinas Medical Center, The Barbara Ann Karmanos Cancer Institute, Lublin Oncology Center, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, McGill University, Columbia University
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4240483744